PMC:7195088 / 17240-17405 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"752","span":{"begin":130,"end":140},"obj":"Chemical"},{"id":"753","span":{"begin":145,"end":164},"obj":"Chemical"},{"id":"918","span":{"begin":81,"end":89},"obj":"Disease"}],"attributes":[{"id":"A753","pred":"tao:has_database_id","subj":"753","obj":"MESH:C558899"},{"id":"A918","pred":"tao:has_database_id","subj":"918","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"t yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T84","span":{"begin":81,"end":89},"obj":"Disease"}],"attributes":[{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"t yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T87","span":{"begin":51,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"t yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T129","span":{"begin":145,"end":164},"obj":"Chemical"},{"id":"T130","span":{"begin":145,"end":154},"obj":"Chemical"},{"id":"T131","span":{"begin":155,"end":164},"obj":"Chemical"}],"attributes":[{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"t yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir "}

{"project":"LitCovid-sentences","denotations":[{"id":"T113","span":{"begin":19,"end":113},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"t yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir "}